A new test for cervical cancer was found to detect all of the cancers in a randomised clinical screening trial of 15,744 women, outperforming both the current Pap smear and human papillomavirus (HPV) test at a reduced cost, according to a study led by Queen Mary University of London.
The study, published in the International Journal of Cancer, compared a new ‘epigenetics-based’ cervical cancer test with Pap smear and HPV tests, and investigated how well it predicted the development of cervical cancer up to five years in advance in a large study of women aged 25-65 in Canada.
As opposed to checking for patterns in the DNA genetic code itself that are indicative of the HPV virus, the new test looks at the naturally-occurring chemical markers that appear on top of the DNA, making up its ‘epigenetic profile’.
‘An enormous development’
Lead researcher Professor Attila Lorincz from Queen Mary’s Wolfson Institute of Preventive Medicine who also helped develop the world’s first test for HPV in 1988, said: “This is an enormous development. We’re not only astounded by how well this test detects cervical cancer, but it is the first time that anyone has proven the key role of epigenetics in the development of a major solid cancer using data from patients in the clinic. Epigenetic changes are what this cervical cancer test picks up and is exactly why it works so well.
“In contrast to what most researchers and clinicians are saying, we are seeing more and more evidence that it is in fact epigenetics, and not DNA mutations, that drives a whole range of early cancers, including cervical, anal, oropharyngeal, colon, and prostate.”
Screening to prevent cervical cancer is typically done through the Pap smear, which involves the collection, staining and microscopic examination of cells from the cervix. Unfortunately, the Pap smear can detect only around 50 per cent of cervical pre-cancers.
A much more accurate cervical screening method involves testing for the presence of DNA from the human papillomavirus (HPV) – the primary but indirect cause of cervical cancer. There are estimated to be around 10 million women in the UK who are infected by HPV.
However, the HPV test only identifies whether or not women are infected with a cancer-causing HPV, but not their actual risks of cancer, which remain quite low. This causes unnecessary worry for the majority of HPV-infected women who receive a positive result but will eventually clear the virus and not develop the disease.
Predicting a person’s risk of cervical cancer
The new test was significantly better than either the Pap smear or HPV test. It detected 100 per cent of the eight invasive cervical cancers that developed in the 15,744 women during the trial. In comparison, the Pap smear only detected 25 per cent of the cancers, and the HPV test detected 50 per cent.
The study also looked more closely at a subset of 257 HPV-positive women which were representatively selected from the large study. The new test detected 93 per cent of pre-cancerous lesions in those women, compared to 86 per cent detected using a combination of the Pap smear and HPV test, and 61 per cent detected using the Pap smear on its own.
Reducing the number of screening appointments needed
Professor Lorincz added: “This really is a huge advance in how to deal with HPV-infected women and men, numbering in the billions worldwide, and it is going to revolutionise screening.
“We were surprised by how well this new test can detect and predict early cervical cancers years in advance, with 100 per cent of cancers detected, including adenocarcinomas, which is a type of cervical cancer that is very difficult to detect. The new test is much better than anything offered in the UK at present but could take at least five years to be established.”
The authors say that using this test in the clinic would reduce the number of visits to the doctor and screening appointments, as high-grade disease would be detected from the start. They also say that if it was fully implemented, it would be cheaper than the Pap smear.
The Latest on: Cervical cancer
via Google News
The Latest on: Cervical cancer
- Jamie Otis Says She's Been Diagnosed With HPV and Has Cervical Dysplasia—Here's What That Meanson December 6, 2019 at 12:30 pm
One is a low-risk type that causes genital warts, and the other is higher-risk and can lead to precancer and cancer. Otis doesn't get into too much detail, but presumably she was diagnosed with a ...
- Beautician, 34, is diagnosed with cervical cancer after rushing to book a smear test when a client broke down about her own resultson December 6, 2019 at 4:01 am
A beautician was diagnosed with cervical cancer after she rushed to book a smear test when her client broke down in tears about her own results. Jamie Lea Church, 34, who runs an eyebrow salon named ...
- Here’s Everything You Need to Know About Cancer Screeningon December 5, 2019 at 4:16 pm
According to the American Cancer Society, screening rates for colorectal, breast, and cervical cancer are lower in Philadelphia than in other areas of Pennsylvania, while 25 percent of the city’s ...
- India saw highest number of cervical cancer deaths in 2018on December 5, 2019 at 10:39 am
NEW DELHI: India recorded the highest estimated number of cervical cancer deaths in 2018, a research paper published in the Lancet Global Health has revealed. The report, Estimates of incidence and ...
- Your Mom Is Wrong: Your Vegetarian Diet Did Not Cause Canceron December 5, 2019 at 10:21 am
I recently was told by my doctor to go see a doctor at the Cancer Institute to be tested for cervical cancer. When I told my mother she freaked out and told me my vegetarian diet was to blame, and ...
- Cervical cancer patient advocate Lorraine Walsh resigns over review ‘inaccuracies’on December 4, 2019 at 1:21 am
Patient advocate Lorraine Walsh, one of the women affected by the CervicalCheck controversy, has resigned from the steering committee of the screening programme. Ms Walsh said she “absolutely” does ...
- Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical canceron December 3, 2019 at 7:03 am
Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that using the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with ...
- Heartbroken husband who lost wife to cervical cancer says her death could have been avoidedon December 2, 2019 at 6:30 pm
A heartbroken husband who lost his wife to cervical cancer four years ago - and only found out in October it might have been avoided - said he is bracing himself for a wave of sad emotion today. Gary ...
- Rwanda leads fight against cervical cancer in Africaon November 27, 2019 at 5:42 pm
Cervical cancer is the fourth most common cancer among women worldwide. But in Africa it is far deadlier than elsewhere, despite being a preventable disease. An ambitious health campaign in Rwanda has ...
- Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cellson November 27, 2019 at 2:41 am
The aim of this study was to explore the potential role of miR-31-3p/Sema4C in regulating EMT in cisplatin-resistant (CR) cervical cancer cells. High expression levels of Sema4C were more frequently ...
via Bing News